<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Indium In 111 Chimeric Monoclonal Antibody G250</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm><n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>In-111 MoAbG250</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A radioimmunoconjugate comprised of the chimeric monoclonal antibody G250 conjugated with the gamma-emitting radioisotope indium In 111. Indium I 111 chimeric monoclonal antibody G250 binds to G250, allowing the localization of G250-expressing tumor cells using gamma scintigraphy. Found in the majority of renal cell carcinomas (RCCs), G250 or carbonic anhydrase isozyme IX (CA IX) is a cell surface tumor-associated antigen (TAA).</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>